{
  "slug": "abalone-bio",
  "name": "Abalone Bio",
  "description": "Abalone Bio develops target-activating antibody drugs using its proprietary Functional Antibody Selection Technology (FAST) platform, which measures functional activity directly at a massive scale. They leverage large activity datasets and machine learning to create highly specific activators for hard-to-drug targets, particularly G-protein coupled receptors (GPCRs), to unlock new therapies with fewer side effects.",
  "url": "https://optimly.ai/brand/abalone-bio",
  "websiteUrl": "https://abalonebio.com/",
  "logoUrl": "https://logo.clearbit.com/abalonebio.com",
  "baiScore": 29.2,
  "bai_tier_status": "active",
  "bai_score_status": "active",
  "archetype": null,
  "archetype_status": "active",
  "category": "Antibody Discovery and Engineering Platforms",
  "categorySlug": null,
  "keyFacts": [],
  "aiReadiness": [],
  "competitors": [],
  "competitorsProse": null,
  "inboundCompetitors": [],
  "aiAlternatives": [],
  "parentBrand": null,
  "subBrands": [],
  "updatedAt": "2026-09-02T01:07:47.406Z",
  "verifiedVitals": {
    "website": "https://abalonebio.com",
    "category": "Biotechnology",
    "what_it_does": "Abalone Bio creates antibodies that activate hard-to-drug targets, specifically focusing on G-protein coupled receptors (GPCRs), to develop therapies with fewer side effects. They utilize a proprietary Functional Antibody Selection Technology (FAST) platform and machine learning, powered by large-scale activity datasets, to discover and design highly specific activating drugs.",
    "primary_audience": "Drug companies",
    "core_product": "Target-activating antibodies",
    "pricing_model": {
      "kind": "custom",
      "detail": null
    },
    "parent_ownership": null
  },
  "intentTags": null,
  "businessProfileClaims": [],
  "timestamp": 1789858334718
}